Kiel Group: QUANTITATIVE AND SYSTEMS ANALYSIS OF (PATHO)PHYSIOLOGICAL SIGNALING NETWORKS
What we do
Network-centric approaches to drug development and cancer treatment have become essential in recent years. However, the function and biological output of signal transduction networks (STN) is context-dependent. My group will study how STN relevant in colon cancer are context- and tissues-specific quantitatively modulated in (patho)physiologically-relevant primary cells and organoids. We will study how STN control cellular phenotypes by investigating how they generate cell type-specific vs. -general functions, and how cancer mutations affect these interactions and outputs. Using protein engineering, we will generate mutations that rewire cancer-relevant STN in a designed fashion. This approach may provide better mechanism-driven diagnostics and treatments.
Colon cancer | 3D tissue models | protein engineering | CRISPR-Cas9 | network rewiring | core signaling pathways
To find out more about our work, to collaborate on a project or for postdoc, PhD and intern opportunities, contact Christina Kiel.
As of September 2017 - funded through an award from Science Foundation Ireland (SFI) - I will be a Principle Investigator at the UCD School of Medicine and Systems Biology Ireland (SBI). Prior to taking up my current position, I held a position as Staff Scientist in the Systems Biology department of the Center for Genomic Regulation (CRG) in Barcelona, Spain. I obtained my PhD degree in the Structural Biology department of the Max-Planck-Institute for Molecular Physiology in Dortmund, Germany, in 2003. For my postdoctoral studies I moved to the department of Structural and Computational Biology at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. My major research area is the quantitative, systems and structural analysis of signaling pathways and protein interaction networks relevant in human diseases.